Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624361 | 0.91 | POLB (0.67) | POLBTDP1CYP1A2EPHX2KDM4E | |
| SCHEMBL13176215 | 0.89 | POLB (1.00) | POLBTDP1CYP1A2EPHX2KDM4E | |
| SCHEMBL4653078 | 0.88 | POLB (0.61) | POLBTDP1CYP1A2EPHX2KDM4E | |
| SCHEMBL19203827 | 0.80 | POLB (0.52) | POLBEPHX2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL12156648 | 0.80 | POLB (0.57) | POLBEPHX2KDM4EALDH1A1KMT2A | |
| SCHEMBL12045719 | 0.80 | POLB (0.80) | POLBTDP1CYP1A2EPHX2KDM4E | |
| SCHEMBL19128259 | 0.80 | POLB (0.80) | POLBTDP1CYP1A2EPHX2KDM4E | |
| SCHEMBL16051304 | 0.79 | — | — | |
| SCHEMBL967287 | 0.79 | — | — | |
| SCHEMBL13853824 | 0.79 | KDM4E (0.55) | POLBEPHX2KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558507-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| CN-119585284-A | Macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2024017859-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | claimed |
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | claimed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | claimed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | claimed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | claimed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| EP-4558507-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119585284-A | Macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024017859-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003007959-A1 | QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-30 | — | — | WO | disclosed |
| US-4147785-A | Method for the treatment of onchocerciasis | Dobbie, Graham J. (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | POLB 1869/4885TDP1 4559/4885CYP1A2 108/4885 |
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | POLB 12/4885TDP1 28/4885CYP1A2 1583/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | POLB 2173/4885TDP1 2026/4885CYP1A2 950/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | POLB 7/4885TDP1 63/4885CYP1A2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.